VEGFA and gastrointestinal stromal tumor: "Angiogenesis"; axitinib is approved for renal cell carcinoma, bevacizumab is approved for metastatic colon, lung, renal, ovarian, GBM, and sunitinib for renal cell carcinoma, GIST and target is VEGF